The global kinase inhibitors market reached $28.1 billion in 2010 and
nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by
2016, a compound annual growth rate (CAGR) of 6.7%.
The U.S. market for kinase inhibitors reached $10.8 billion in 2010 and
came down to $10.4 billion in 2011. The market is expected to reach $11.6
billion by 2016, a CAGR of 2.2%.
The U.S. market for monoclonal antibody kinase inhibitors was $7.6 billion
in 2010 and came down to $6.6 billion in 2011. This segment is expected to
decrease at a CAGR of -4% and total $5.4 billion in 2016.
SUMMARY FIGURE
GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
($ MILLIONS)
Source: BCC Research
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global market for kinase inhibitors. The key
objective is to present a comprehensive analysis and the future direction of
kinase inhibitors to provide an important tool for the usage of these types of
enzyme inhibitors.
This report explores present and future strategies within the kinase
inhibitors market, which includes tyrosine inhibitors, multi-target kinase
inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase
inhibitors. The direction of the market, its setbacks and the needs of the
market are discussed in this report. The classifications, comparisons and
usage of these types of enzyme inhibitors are also examined in the report.
A detailed analysis of the kinase inhibitors industry structure has been
conducted. Revenues are broken down by region. Sales figures are estimated for
the five-year period from 2011 through 2016.
Applications for kinase inhibitors are also discussed separately in the
report, with emphasis on the usage of the inhibitors in therapeutic categories
and various disease sectors. The report also covers significant patents and a
summary of patents awarded in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of kinase inhibitors has revealed their
target-specific functionality in being able to provide therapeutic treatments
for various chronic diseases. Modern industries have now begun to explore the
advantages of kinase inhibitors in their productions and processes. This has
led to the steady market for them.
R&D spending along with increasing competition, patent expiries and new
technologies are directing kinase inhibitors to new directions. The new
advancements, new product launches and the changing lifestyle have influenced
the market to grow in the foreseeable future. This study looks at almost all
the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in
this report. This study also discusses the strengths and weaknesses of each
type/ technology in light of the new technologies, growing competition and
changing customer needs.
SCOPE OF THE STUDY
The scope of this study encompasses kinase inhibitors in pharmaceutical and
biotechnology markets. BCC analyzes each market and its applications,
regulatory environment, technology, market projections and market share.
Technological issues include the latest trends and developments. The emerging
market for enzyme inhibitors includes India, China, Japan, South Korea,
Taiwan, Canada, Africa, Australia and New Zealand and others countries.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals and many other sources. Data were collected
through interviews and correspondence with manufacturers of enzyme inhibitors
and technical experts. Projections were based on estimates such as the current
number of end users, potential end users, mergers and acquisitions, and market
trends.
INFORMATION SOURCES
Many companies active in the kinase inhibitor industry were surveyed to obtain
data for this study. Included were manufacturers and end users of kinase
inhibitors in therapeutic categories and various disease sectors industries.
Data were gathered from various industry sources. BCC spoke with officials
within the industry, consulted newsletters, company literature, product
literature, and a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were
conducted. In addition, data were compiled from current financial, trade and
government sources.
ABOUT THE AUTHOR
A team of professionals in the biotechnology industry carried out this study.
The project manager is Shalini S. Dewan, who holds a master's degree in
pharmaceutical chemistry and has over 14 years of industry experience. Among
the research topics she has covered are studies on compounds of potential
pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was
awarded a Gold Medal by the Prime Minister of India for her work and has
worked with top companies in India and in the U.S.
Table of Contents
Table of Contents
Kinase Inhibitors: Global Markets -- Focus on the U.S.
Chapter - 1: INTRODUCTION - Complimentary
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
Table Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
Figure Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
Chapter - 3: OVERVIEW
DEFINITIONS
ENZYME INHIBITORS
KINASE INHIBITORS
CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION
CLASSIFICATION BY SITE OF ACTION
Chapter - 4: REGULATORY ASPECTS
MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS
Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE
KINASE INHIBITORS
Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS
Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS
Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE
KINASE INHIBITORS
Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE
INHIBITORS
Figure 12: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016
Figure 13: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, 2009-2016
Figure 14: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016
Figure 15: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016
Figure 16: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
Figure 17: U.S. MARKET FOR KINASE INHIBITORS, 2009-2016
Figure 18: U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016
Figure 19: U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
Figure 20: U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR,
2009-2016
Figure 21: U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016
Figure 22: U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016
Figure 23: U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016
Figure 24: U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010
Figure 25: U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR
MANUFACTURERS, 2010
Figure 26: U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010
Figure 27: U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS,
2010
Figure 28: U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016
Figure 29: U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, 2009-2016
Figure 30: U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016
Figure 31: U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016
Figure 32: MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010
Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
Figure 34: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
Figure 35: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012
Figure 36: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012
Figure 37: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO
END OF FEBRUARY 2012
Figure 38: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008
TO END OF FEBRUARY 2012
Figure 39: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010 - 2012
Figure 40: PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012
Kinase Inhibitors: Global Markets -- Focus on the U.S. published by BCC Research in June 30, 2012. This report consists of 122 Pages and the price starts from US $ 4400.
